Slide 1: End of year results
End of year results 14th March 2018
Slide 2: Disclaimer
Disclaimer This presentation is the sole responsibility of the directors of EKF Diagnostics Holdings plc (the “Company”). N+1 Singer Advisory LLP (“N+1 Singer”), which is authorised and regulated by the Financial Conduct Authority, is acting as the nominated adviser and broker to the Company. This p
Slide 3: Agenda
Agenda Slide no. 4. 2017 Highlights 6. 2017 Financial performance 7. Income statement 8. Business Unit performance 9. Geographic performance 11. 2018 Outlook 12. Appendices
Slide 4: 2017 Highlights
2017 Highlights 41.6 • Revenues up 8% to £41.6m (2016 £38.6m) 38.6 37.1 • b-HB Liquicolor sales up £1.1m • DiaSpect Tm sales up £0.5m 31.8 30.0 • Quo-Test A1c sales up £0.7m • Sold c. 14,556 analysers and 70.2m tests 26.1 • AEBITDA £9.3m (2016 £6.1m) • £M Net cash £7.0m (2016 £2.2m) • Closure of Pol
Slide 5: EKF Diagnostics: A global diagnostics company
EKF Diagnostics: A global diagnostics company Key product portfolio: • Hemoglobin and hematocrit • HbA1c • Glucose • Lactate • Beta-Hydroxybutyrate Global reach: • A large distribution network of over 300 distributors from 115 countries • OEM and co-branded partnerships 5
Slide 6: 2017 Financial performance
2017 Financial performance Cash generated from • Gross profit up 25% to £22.9m (2016: £18.3m) operations 12 • AEBITDA up 52% to £9.3m (2016: £6.1m) Millions • Cash and cash equivalents: £8.2m (2016: £7.9m) 10 • Cash generated from operations: £10.1m (2016: £8.8m) 8 6 4 2 0 -2 -4 2012 2013 2014 2015
Slide 7: Income Statement: Extract
Income Statement: Extract FY 2017 £k FY 2016 £k +/- £k Revenue 41,584 38,589 2,995 Gross profit 22,863 18,322 4,541 GM % 55.0% 47.5% - Admin. costs (17,582) (18,734) 1,152 Other income 52 85 (33) Operating (loss)/profit 5,333 (327) 5,660 AEBITDA 9,304 6,139 3,165 7
Slide 8: Business Unit performance
Business Unit performance FY 2017 £k FY 2016 £k +/- % Point of Care Total 28,987 26,538 +9% Hematology 12,911 11,704 +10% Diabetes 11,547 10,203 +13% Others 4,529 4,631 (2%) Central Laboratory Total 12,597 12,051 +4% Total 41,584 38,589 +8% 8
Slide 9: Geographical performance
Geographical performance EMEA LIFE SCIENCES FY 2017 £15,541 FY 2017 £2,157 £’000 £’000 APAC FY 2017 £4,207 USCAN FY 2017 £16,796 £’000 Revenue FY 2017 £k FY 2016 £k +/- £k LATAM APAC 4,207 3,954 +253 FY 2017 £2,883 EKF LS 2,157 2,489 (332) £’000 EMEA 15,541 13,566 +1,975 LATAM 2,883 3,712 (829_ USCA
Slide 10: Regulatory update
Regulatory update Product registrations • Significant investment in clinical trials in USA • China FDA registration of Quo-Test in lab testing phase • Brazilian registration for Hemo Control, DiaSpect Tm, Quo-Test and Quo-Lab • Mexico, Brazil and Colombia registrations for β-HB due to complete in H1
Slide 11: 2018 Outlook
2018 Outlook • Growth opportunities from new registrations, new products and customers: – Clinical trials in USA – Quo-Lab registration in Mexico – Launch of Lactate Scout 4.0 expected in H2 2018 – FDA pre-submission for use of lactate in medical applications, specifically sepsis – β-HB sales expans
Slide 12: Financial report
Appendix 1 Financial report End of year results 2017
Slide 13: Consolidated Income Statement
Consolidated Income Statement FY 2017 £k FY 2016 £k +/- £k Revenue 41,584 38,589 2,995 Gross profit 22,863 18,322 4,541 GM % 55.0% 47.5% Administrative expenses (18,186) (18,734) 548 Other income 52 85 (33) AEBITDA 9,304 6,139 3,165 Share based payments (1,514) (973) 541 Exceptional items 1,562 (532
Slide 14: Balance Sheet / Cash Flow
Balance Sheet / Cash Flow FY 2017 £k FY 2016 £k +/- £k Intangible assets 43,600 46,503 (2,903) Property, plant, equipment 12,121 12,124 (3) Inventories 5,638 6,025 (387) Trade / other receivables 7,396 9,370 (1,974) Cash and cash equivalents 8,203 7,874 329 Deferred considerations 1,062 693 369 Trad
Slide 15: Balance Sheet: Assets
Balance Sheet: Assets Selected items FY 2017 £k FY 2016 £k +/- £k Non-current assets Property, plant, equipment 12,121 12,124 (3) Intangible assets 43,600 46,503 (2,903) Investments 152 152 0 Deferred tax assets 34 371 (337) Total non-current assets 55,907 59,150 (3,243) Current assets Inventories 5
Slide 16: Balance Sheet: Equity and Liabilities
Balance Sheet: Equity and Liabilities FY 2017 FY 2016 Selected items +/- £k £k £k Equity attributable Total equity 60,498 60,971 (473) Non-current liabilities Borrowings 872 1,130 (258) Deferred tax liabilities 3,467 3,751 (284) Total non-current liabilities 4,339 4,881 (542) Current liabilities Tra
Slide 17: Cash Flow
Cash Flow FY 2017 £k FY 2016 £k +/- £k Cash and cash equivalents at 7,874 2,017 5,857 beginning of period Cash from (used in) operating 9,053 8,943 597 activities Cash used in investing activities (2,032) (1,426) (672) Cash used in financing activities (6,840) (2,113) (4,727) Net increase / (decreas
Slide 18: Business Unit performance
Appendix 2 Business Unit performance
Slide 19: Hematology FY 2017
Hematology FY 2017 Hematology range • Revenues up £1,207k (10%) DiaSpect Tm • Hemo Control/H2 up £430k (7%) HemataStat II • DiaSpect Tm/CompoLab up £500k (23%) Hemo Control • HemataStat II up £278k (18%) HemoPoint H2 UltraCrit 2017 £k 2016 £k +/- £k +/- % Hematology 12,911 11,704 1,207 10% analysers
Slide 20: Diabetes FY 2017
Diabetes FY 2017 Diabetes range • Revenues up £1,343k (13%) Biosen • Biosen up £454k (10%) Quo-Lab A1c • Quo-Test and Quo-Lab up £671k (14%) Quo-Test A1c STAT-Site M b-HB 2017 £k 2016 £k +/- £k +/- % Diabetes analysers 11,547 10,203 1,344 13% and tests 20
Slide 21: Central Laboratory
Central Laboratory Clinical chemistry, benchtop lab analysers and enzymes • Revenues up £546k (5%): Central Lab range Clinical chemistry • β-HB Liquicolor reagent up £1,068k (17%) Beta-Hydroxybutyrate • Clinical chemistry down £88k (4%) including sales of Altair 240 analysers Small lab analysers • D
Slide 22: Central Laboratory
Central Laboratory Beta-Hydroxybutyrate LiquiColor test • b-HB Liquicolor 2017 sales: b-HB Liquicolor revenues • 2017 revenues of £7,225k v 2016 £6,157k (up by 17%) 8 • US hospitals using b-HB on clinical chemistry analysers: 7 • December 2017: c.1,190 6 • December 2016: 1,111 5 • December 2015: 1,0
Slide 23: Thanks for your attention
Thanks for your attention